NovoCure annual shares outstanding
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
NovoCure Shares Outstanding History (NVCR)
NovoCure reported 112.5M shares outstanding at the end of fiscal 2025.
View full NovoCure company overviewNovoCure annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 112.5M | 4.0M | +3.66% |
| 2024 | 2024-12-31 | 108.5M | 1.4M | +1.35% |
| 2023 | 2023-12-31 | 107.1M | 2.0M | +1.93% |
| 2022 | 2022-12-31 | 105.0M | 1.1M | +1.04% |
| 2021 | 2021-12-31 | 104.0M | 1.6M | +1.60% |
| 2020 | 2020-12-31 | 102.3M | 2.8M | +2.82% |
| 2019 | 2019-12-31 | 99.5M | 6.3M | +6.73% |
| 2018 | 2018-12-31 | 93.3M | 3.8M | +4.22% |
| 2017 | 2017-12-31 | 89.5M | 2.4M | +2.77% |
| 2016 | 2016-12-31 | 87.1M | 3.3M | +3.92% |
| 2015 | 2015-12-31 | 83.8M | 70.3M | +523.75% |
| 2014 | 2014-12-31 | 13.4M | — | — |
NovoCure quarterly shares outstanding
Q4.14
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 116.4M | 4.6M | +4.15% |
| Q1 2026 | 2026-03-31 | 115.8M | 4.3M | +3.89% |
| Q4 2025 | 2025-12-31 | 112.5M | 4.0M | +3.66% |
| Q3 2025 | 2025-09-30 | 112.0M | 3.9M | +3.59% |
| Q2 2025 | 2025-06-30 | 111.8M | 3.8M | +3.50% |
| Q1 2025 | 2025-03-31 | 111.5M | 3.9M | +3.60% |
| Q4 2024 | 2024-12-31 | 108.5M | 1.4M | +1.35% |
| Q3 2024 | 2024-09-30 | 108.1M | 1.4M | +1.27% |
| Q2 2024 | 2024-06-30 | 108.0M | 1.4M | +1.32% |
| Q1 2024 | 2024-03-31 | 107.6M | 1.4M | +1.33% |
| Q4 2023 | 2023-12-31 | 107.1M | 2.0M | +1.93% |
| Q3 2023 | 2023-09-30 | 106.7M | 1.8M | +1.72% |
| Q2 2023 | 2023-06-30 | 106.6M | 1.9M | +1.79% |
| Q1 2023 | 2023-03-31 | 106.2M | 1.6M | +1.56% |
| Q4 2022 | 2022-12-31 | 105.0M | 1.1M | +1.04% |
| Q3 2022 | 2022-09-30 | 104.9M | 1.1M | +1.08% |
| Q2 2022 | 2022-06-30 | 104.7M | 1.1M | +1.05% |
| Q1 2022 | 2022-03-31 | 104.6M | 1.4M | +1.33% |
| Q4 2021 | 2021-12-31 | 104.0M | 1.6M | +1.60% |
| Q3 2021 | 2021-09-30 | 103.8M | 2.1M | +2.05% |
| Q2 2021 | 2021-06-30 | 103.6M | 2.6M | +2.59% |
| Q1 2021 | 2021-03-31 | 103.2M | 2.8M | +2.81% |
| Q4 2020 | 2020-12-31 | 102.3M | 2.8M | +2.82% |
| Q3 2020 | 2020-09-30 | 101.7M | 2.8M | +2.81% |
| Q2 2020 | 2020-06-30 | 101.0M | 3.2M | +3.23% |
| Q1 2020 | 2020-03-31 | 100.4M | 4.7M | +4.88% |
| Q4 2019 | 2019-12-31 | 99.5M | 6.3M | +6.73% |
| Q3 2019 | 2019-09-30 | 98.9M | 5.9M | +6.39% |
| Q2 2019 | 2019-06-30 | 97.9M | 5.4M | +5.79% |
| Q1 2019 | 2019-03-31 | 95.7M | 5.3M | +5.86% |
| Q4 2018 | 2018-12-31 | 93.3M | 3.8M | +4.22% |
| Q3 2018 | 2018-09-30 | 93.0M | 3.7M | +4.09% |
| Q2 2018 | 2018-06-30 | 92.5M | 3.9M | +4.37% |
| Q1 2018 | 2018-03-31 | 90.4M | 2.3M | +2.57% |
| Q4 2017 | 2017-12-31 | 89.5M | 2.4M | +2.77% |
| Q3 2017 | 2017-09-30 | 89.4M | 3.6M | +4.17% |
| Q2 2017 | 2017-06-30 | 88.6M | 2.9M | +3.33% |
| Q1 2017 | 2017-03-31 | 88.1M | 3.7M | +4.39% |
| Q4 2016 | 2016-12-31 | 87.1M | 3.3M | +3.92% |
| Q3 2016 | 2016-09-30 | 85.8M | 73.3M | +589.94% |
| Q2 2016 | 2016-06-30 | 85.8M | — | — |
| Q1 2016 | 2016-03-31 | 84.4M | — | — |
| Q4 2015 | 2015-12-31 | 83.8M | 70.3M | +523.75% |
| Q3 2015 | 2015-09-30 | 12.4M | — | — |
| Q4 2014 | 2014-12-31 | 13.4M | — | — |
NovoCure Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. NovoCure share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
NovoCure used $5,000 to repurchase common stock in fy 2015. The latest reported quarter showed $0 of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2015 | 2015-12-31 | $5,000 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
NovoCure shares outstanding trends
Over the last five fiscal years, NovoCure's shares outstanding moved from 102.3M to 112.5M, a change of 10.2M. The latest reported quarter, Q2 2026, shows 116.4M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovoCure source filings ↗Community posts
Novocure raises annual revenue and EBITDA targets as patient numbers grow
Novocure ($NVCR) lifted its 2026 revenue forecast to $736–$743 million from $710–$725 million and its adjusted EBITDA outlook to $24–$34 million from $0–$15 million. Third-quarter 2026 revenue increased 16% to $193.4 million, supported by 1 ...
